NASDAQ:PMN Promis Neurosciences Q1 2024 Earnings Report $0.54 -0.01 (-1.42%) Closing price 04:00 PM EasternExtended Trading$0.54 +0.00 (+0.37%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Promis Neurosciences EPS ResultsActual EPS-$0.19Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/APromis Neurosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APromis Neurosciences Announcement DetailsQuarterQ1 2024Date5/14/2024TimeN/AConference Call DateMonday, May 13, 2024Conference Call Time6:00PM ETUpcoming EarningsPromis Neurosciences' Q3 2025 earnings is scheduled for Thursday, November 13, 2025, with a conference call scheduled on Wednesday, November 12, 2025 at 6:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) Promis Neurosciences Earnings HeadlinesProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer's Trial of PMN310September 3, 2025 | globenewswire.comProMIS Neurosciences reports Q2 EPS (29c) vs (13c) last yearAugust 13, 2025 | msn.comNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $25 trillion AI revolution — one that Nvidia’s CEO himself has called a “multi-trillion-dollar future industry” — and he’s uncovered a little-known stock 168 times smaller than Nvidia that could be positioned to ride this breakthrough.October 7 at 2:00 AM | Brownstone Research (Ad)ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate HighlightsAugust 13, 2025 | globenewswire.comProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer's Association International ConferenceJuly 29, 2025 | globenewswire.comProMIS Neurosciences Announces Private Placement FinancingJuly 28, 2025 | globenewswire.comSee More Promis Neurosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Promis Neurosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Promis Neurosciences and other key companies, straight to your email. Email Address About Promis NeurosciencesPromis Neurosciences (NASDAQ:PMN), Inc. is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapeutics for central nervous system disorders. The company’s research programs target cognitive impairment and other neurological symptoms associated with diseases such as Alzheimer’s disease and multiple sclerosis. Leveraging a proprietary small‐molecule discovery platform, Promis Neurosciences advances both preclinical and early clinical candidates designed to modulate neural pathways involved in memory, learning and neuroinflammation. The company’s pipeline reflects a commitment to addressing unmet needs in neurology by optimizing compound profiles for safety, selectivity and central nervous system penetration. Promis Neurosciences collaborates with academic institutions and industry partners to accelerate its research and development efforts. These strategic alliances support biomarker identification, translational studies and clinical trial design, aiming to streamline candidate advancement and enrich patient selection strategies. The company is headquartered in the United States and its common stock trades on the Nasdaq stock exchange under the symbol PMN.View Promis Neurosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 Earnings Upcoming Earnings PepsiCo (10/9/2025)Fastenal (10/13/2025)BlackRock (10/14/2025)Citigroup (10/14/2025)The Goldman Sachs Group (10/14/2025)Johnson & Johnson (10/14/2025)JPMorgan Chase & Co. (10/14/2025)Wells Fargo & Company (10/14/2025)ASML (10/15/2025)Abbott Laboratories (10/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
